Physician profile
William J Strohman
NPI 1124086673
$3,462.40
in general payments reported to CMS, 2019-2025
42 companies · $950 in 2025
The $950 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $197 · 2021: $422 · 2022: $414 · 2023: $530 · 2024: $628 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.99 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.49 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $295.71 | 2020-2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $269.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $261.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $156.57 | 2019-2024 | Evenity, Prolia |
| Idorsia Pharmaceuticals US INC | $108.71 | 2022-2024 | Quviviq |
| Abbott Laboratories | $107.52 | 2024-2025 | Freestyle Libre 3, Octrode |
| Pfizer INC. | $95.47 | 2019-2025 | |
| Exact Sciences Corporation | $95.06 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $84.27 | 2025 | |
| Allergan, INC. | $74.20 | 2019-2020 | |
| Astellas Pharma US INC | $63.59 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $62.86 | 2019-2024 | Nucala |
| Phadia US INC. | $60.14 | 2022-2023 | Immunocap |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Strohman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.